HiringSelective
60/100
1 relevant signal
TA
Technology · United States
Tempus AI
Current work outlook
Tempus AI was selected for an ARPA-H award of up to $9.5 million to build and clinically validate an autonomous AI agent for heart-failure care. The program includes a multi-center prospective study and builds on existing Tempus clinical AI products.
Updated September 9, 2026 · Evidence from public sources
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityNot enough data
We need a relevant verified event before scoring this dimension.
Financial healthMixed
62/100
1 relevant signal
InnovationAccelerating
68/100
1 relevant signal
What moved the outlook
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗Tempus AI wins up to $9.5 million to develop an autonomous cardiology agent
Tempus AI was selected for an ARPA-H award of up to $9.5 million to build and clinically validate an autonomous AI agent for heart-failure care. The program includes a multi-center prospective study and builds on existing Tempus clinical AI products.
Employee impact
Read full analysis →This creates a defined, externally funded program for clinical AI, data integration, validation and regulated-product work. The award is capped at up to $9.5 million, so candidates should verify project duration, funding milestones and whether the role is attached to the program.